GERN$0.89445.47%-0.0518
After Hours: 0.89-0.00 -0.49%
Geron Corp (GERN)
Date: 2026-10-30 16:00O: 0.9300H: 0.9381L: 0.8606C: 0.8944Vol: 18.80M
Geron Corp stock is traded at $0.8944, with a volume of 18,803,922. It is down -5.47% in the last 24 hours and down -27.28% over the past month. Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Previous Close:
$0.9462
Open:
$0.93
24h Volume:
18,803,922
Relative Volume:
1.01
Market Cap:
$574.63M
Revenue:
$196.12M
Net Income/Loss:
-$69.59M
P/E Ratio:
-
EPS:
-$0.1043
Net Cash Flow:
-$126.13M
1W Performance:
-20.14%
1M Performance:
-27.28%
6M Performance:
-41.92%
1Y Performance:
-27.87%
1-Day Range:
$0.8606$0.9381
1-Week Range:
$0.84$1.19
52-Week Range:
$0.84$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron CorpSector
HealthcareIndustry
BiotechnologyPhone
(650) 473-7700Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, USACompare GERN vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN Geron Corp | $0.8944 | $574.63M | $196.12M | -$69.59M | -$126.13M | -$0.1043 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Geron Corp Stock (GERN) Upgrades & Downgrades
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Geron Corp Stock (GERN) Insider Trading
- ROBERTSON MICHELLEFeb 18 '26EVP, CHIEF FINANCIAL OFFICER
- Transaction
- Sale
- Cost
- $1.94
- #Shares
- 9,855
- Value ($)
- 19,119
- #Shares Total
- 17,645
- JAMES ZIEGLERDec 15 '25Officer
- Transaction
- Proposed Sale
- Cost
- $1.37
- #Shares
- 20,000
- Value ($)
- 27,400
- #Shares Total
- 0
